Genomic variations associated with attenuation in Mycobacterium avium subsp paratuberculosis vaccine strains by Bull, TJ et al.
Bull et al. BMC Microbiology 2013, 13:11
http://www.biomedcentral.com/1471-2180/13/11RESEARCH ARTICLE Open AccessGenomic variations associated with attenuation in
Mycobacterium avium subsp. paratuberculosis
vaccine strains
Tim J Bull1*, Alex Schock2, J Michael Sharp2, Mandisa Greene3,5, Iain J McKendrick4, Jill Sales4,
Richard Linedale1 and Karen Stevenson3Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) whole cell vaccines have been widely used
tools in the control of Johne’s disease in animals despite being unable to provide complete protection. Current
vaccine strains derive from stocks created many decades ago; however their genotypes, underlying mechanisms
and relative degree of their attenuation are largely unknown.
Results: Using mouse virulence studies we confirm that MAP vaccine strains 316 F, II and 2e have diverse but
clearly attenuated survival and persistence characteristics compared with wild type strains. Using a pan genomic
microarray we characterise the genomic variations in a panel of vaccine strains sourced from stocks spanning over
40 years of maintenance. We describe multiple genomic variations specific for individual vaccine stocks in both
deletion (26–32 Kbp) and tandem duplicated (11–40 Kbp) large variable genomic islands and insertion sequence
copy numbers. We show individual differences suitable for diagnostic differentiation between vaccine and wild type
genotypes and provide evidence for functionality of some of the deleted MAP-specific genes and their possible
relation to attenuation.
Conclusions: This study shows how culture environments have influenced MAP genome diversity resulting in large
tandem genomic duplications, deletions and transposable element activity. In combination with classical selective
systematic subculture this has led to fixation of specific MAP genomic alterations in some vaccine strain lineages
which link the resulting attenuated phenotypes with deficiencies in high reactive oxygen species handling.
Keywords: Mycobacterium avium subspecies paratuberculosis, Vaccine, Comparative genomics, Variable genomic
island, Attenuation, MicroarrayBackground
Mycobacterium avium subspecies paratuberculosis
(MAP) is a proven enteric pathogen with a wide host
range that includes many domestic and wild animals [1].
It is the causal agent of Johne’s disease (JD) in animals
which is particularly common in countries with signifi-
cant dairy industries leading to considerable economic
losses [2]. MAP can infect, disseminate and persist in
humans and has been suggested as a contributory factor
in the development of Crohn’s disease [3].* Correspondence: tim.bull@sgul.ac.uk
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reproduction in any medium, provided the orMAP vaccines are a major tool used in the control of
JD in animals and can be highly profitable [4]. They have
advantages over herd management [5] and culling strat-
egies [6] in being more cost efficient, easier to imple-
ment on a wide scale and less reliant on diagnostic
testing. It is clear however, that although able to prevent
a majority of animals from reaching onset of clinical dis-
ease, their current formulations provide incomplete pro-
tection against infection and shedding [7-9], thus failing
to eradicate the organism [10]. Most current whole cell
vaccine preparations rely on subcultures of classic
strains that were generated over 70 years ago [11] and
some evidence suggests that, for killed preparations at
least, more recently acquired local virulent strain types. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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BCG has shown that frequent in vitro passage of strains in
different laboratories led to significant alterations in gen-
omic profiles and diversities in attenuation and immuno-
genicity [13]. It is of importance therefore to derive
accurate definitions of MAP vaccine genotypes to better
standardize vaccine manufacture and understand the crit-
ical mechanisms determining vaccine attenuations and
protective efficacies.
The distribution and worldwide use of MAP vaccines
has continued since live ‘attenuated’ strains were selected
in France (1924) and the UK (1940) using a method of
sequential passage similar to that applied for the gener-
ation of BCG [14]. The degree and mechanism under-
lying their attenuation however is uncertain as virulence
studies were not performed in any detail. Concerns in
the 1980’s regarding the use of live vaccine strains be-
cause of low shelf life and spread to the environment
promoted the use of killed vaccine formulations. These
were based on various combinations of three MAP
strains comprising strain 2e from the UK, strain II from
Canada and 316 F. A combination of these were used as
live preparations for Norwegian goats in the 1960’s and
1970’s [15] and as a killed preparation delivered in min-
eral oil to Icelandic sheep in the 1950’s [16]. Live vaccine
formulations of 316 F alone were used in the 1960’s and
70’s in the UK [17] and Cyprus [18], 1980’s in Hungary
[19], 1990’s in Germany [20] and Spain [21] and up until
2002 in New Zealand [22]. Killed preparations of 316 F
alone have been used extensively worldwide [23] and are
still available for commercial use. These strains, due to
the difficulty in retaining mycobacteria in frozen seed
stocks, have been maintained through regular subculture
on a variety of laboratory in-house media. It is unsurpris-
ing therefore, that some reports suggest strain adaptation
to growth in specialized media with loss of Mycobactin J
dependence [24] and genome diversity [25] has occurred
amongst some lineages.
In this work we demonstrate attenuation and differential
virulence of vaccine strains 2e, II and 316 F in a mouse
model and use a full MAP genome microarray, supported
by PCR and sequencing to investigate the genomic shifts
of vaccine strains from a variety of lineages, including one
recently resuscitated 316 F strain, originally lyophilised in
1966. We describe large genomic regions with deletions
and tandem duplications uniquely associated with each
vaccine clade, demonstrate the functionality of some of
these deleted genes and hypothesise as to their role in
virulence attenuation.
Results
Comparative Genomic Hybridisation of vaccine strains
MAPAC hybridisations comparing each vaccine strain
against a MAPK10 reference control were made (induplicate) and averaged values displayed as scatterplots
(Figure 1a and Figure 1b). Significant loss of signals
in contiguous genes representative of large variable
genomic island (vGI) deletions were identified in a 26.8
Kbp region of 316FNOR1960 (vGI-19: MAP3714-
MAP3735c; Table 1) and a 32.8 Kbp region in both
IIUK2000 and 2eUK2000 (vGI-20: MAP1694-MAP1727;
Table 2). Two fold increases in signals were also seen in
contiguous genes within a 24.9 Kbp region of IIUK2000
(vGI-21: MAP2705c-MAP2733c; Table 3), a 40.7 Kbp re-
gion of 316 F-NLD1978 (vGI-22: MAP1750-MAP1789,
Table 4) and a 11.0 Kbp 316FUK2000 (vGI-1b:
MAP0096c-MAP0104; Table 5).
Signal ratios from genes in multiple copies in the genome
such as insertion elements are more difficult to interpret
as changes in signal are related to copy number. Neverthe-
less IS900 signal ratios were significantly reduced in
IIUK2000, 2eUK2000, 316FNOR1960, 316v, 316FUK2000
and elevated in 316FNLD1978 and 316FNLD2008.
Increases in signals for IS1652-like elements were also seen
in IIUK2000, 2eUK2000, 316FUK2000, 316FNLD1978
and 316FNLD2008 and decreases for this element in
316FNOR1960. IS256-like elements were more abundant
in 2eUK2000 and also raised in 316v and 316FUK2000 but
decreased in 316FNOR1960 relative to MAPK10. IS1311-
like elements were increased in 316v and decreased in
316FNOR1960. One of these elements (MAP0104) borders
the previously described vGI-1b region which is bounded
by short inverted repeat sequences and duplicated in MAP
type III strains [26].
The tandem duplication vGI-21 was confirmed using
primer set MAP2705.seq2 and MAP2733.R (Table 6)
orientated to amplify only the end of one tandem repeat
and the beginning of the other. This produced an
amplicon of 651 bp only with vaccine strain IIUK2000
and IIUK2001 (Additional File 1). Sequencing of this
amplicon showed the duplication event to occur relative
to the reference strain K10 genome (GenBank accession
AE016958) at position 3066285 within the first copy of
MAP2733c (truncated at aa251) followed by a unique re-
gion of 16 bp (CCAGCTCGGCCACCCG) and then a
second copy of MAP2704 (truncated at aa138) followed
by the vGI-21 duplication thus comprising a tandem du-
plication of 24,971 bp spanning 29 ORFs (MAP2705c-
MAP2733c). PCR using primer pairs specific for this
tandem duplication MAP2705.seq2 and MAP2733.R was
negative for all other strains included in this study.
vGI-22 was confirmed as a tandem duplication using
primer set MAP1789.F and MAP1750.R (Table 6) which
produced an amplicon of 2967 bp with vaccine strain
316 F-NLD1978 only. Sequencing of this region showed
the duplication event to comprise 40,744 bp spanning 41
ORFs (MAP1749-MAP1789). The duplication site occurs
at Genbank accession AE016958 position 1952589 within
a b
Figure 1 Microarray scatterplots comparing genomes of test MAP vaccine strains against MAP K10 reference strain.
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by an overlap region of 3 bp (GGG) and then the second
copy of MAP1748c (truncated at aa143) followed by the
vGI-22 duplication. PCR with primer pairs specific for
this tandem duplication (MAP1789.F, MAP1750.R) was
negative for all other strains included in this study.
Several attempts to localise the vGI-1b duplication
using outward facing primers around the region in a
similar manner to vGI-21 and vGI-22 were unsuccessful
and this region may not be present in 316UK2000 as a
tandem duplication. qPCR was performed using both
MAP0101 and MAP0103 specific primer pairs located
inside vGI-1b and the relative copy number of each
compared against a single copy genome target control
represented by primer pairs to MAP2114c. Both
MAP0101 and MAP0103 pairs showed a doubling of
signal strengths relative to MAP2114c in strain
316FUK2000 whilst all other strains included in this
study showed signal consistent with single copies of
both these genes (Table 7).IS900 insertion site analysis
To determine which IS900 sites were absent relative to the
K10 reference genome, PCR primers were designed to spe-
cifically amplify each of the known 17 IS900 loci (Table 6).
These were used to confirm the insertion of IS900 into each
locus in the reference strain K10 and were also all positive
in all 316 F strains and a caprine isolate CAM87. Both
vaccine strains IIUK2000 and 2eUK2000 were missing
IS900(MAP1722) whereas IS900(MAP1033) was also
missing from vaccine strain 2eUK2000 but present in all
other strains including vaccine strain IIUK2000. Compara-
tive qPCR of IS900 copy number relative to MAP2114c,
demonstrated a range of IS900 copies in vaccine strains that
corresponded to the trend in hybridisation signals observed
in MAPAC scatterplots (Figure 1a & 1b). The ratio of copy
number however was surprisingly higher than predicted,
with vaccine strains IIUK2000 and 2eUK2000 having only
13 copies whilst MAPK10 and 316 F strains gave signals
correspondent with 16–19 relative IS900 copy numbers
(Table 7).
Table 1 Deleted region (vGI-19) in 316FNOR1960
Gene Name Putative function Process
MAP3714 fadD2 LuxE like Acyl-coA synthase Fatty Acid Metabolism
MAP3715 Unknown
MAP3716c fadE6 Acyl-CoA dehydrogenase Fatty Acid Metabolism
MAP3717c Dipeptidyl aminopeptidase
MAP3718c Transcriptional regulator
MAP3719 Glyoxalase Anti-host killing factor
MAP3720 Unknown
*MAP3721 polyketide synthase associated protein PapA2 Cell Adhesion
*MAP3722 Unknown
*MAP3723c Transcriptional regulator
*MAP3724 Unknown
*MAP3725 PPE-1 Signalling
*MAP3726 fepD ABC-type cobalamin/Fe3+ siderophore transporter Transporter
*MAP3727 fepC ABC-type cobalamin/Fe3+−siderophore transporter Transporter
*MAP3728 fepB ABC-type cobalamin/Fe3+−siderophore transporter Transporter
*MAP3729 tauD Taurine catabolism dioxygenase Taurine resistance
*MAP3730 tehB O-methyltransferase Tellurite resistance
*MAP3731c ABC non-ribosomal derived peptide transporter Transporter
*MAP3732c ABC non-ribosomal derived peptide transporter Transporter
*MAP3733c ABC non-ribosomal derived peptide transporter Transporter
*MAP3734c ABC non-ribosomal derived peptide transporter Transporter
*MAP3735c ABC non-ribosomal derived peptide transporter Transporter
* = MAP specific genes.
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One MAP specific gene predicted to be deleted in vGI-
19 was MAP3730 (Table 1), a S-adenosylmethionine
-dependent methyltransferase with homologues to tellur-
ite resistance genes (tehB) involved in bacterial virulence
and persistence [27,28]. The functionality of this gene in
mycobacteria has not previously been investigated. Using
a solid culture plate assay we compared tellurite resist-
ance (MIC) of MAP strains with and without the vGI-19
deletion (Table 7). This demonstrated a wide MIC range
(8 - >512 μg/ml) between strains, with significant
reductions associated with vGI-19 (316FNOR1960) dele-
tion over full genome complement strains. Of note how-
ever was the very low level of tellurite resistance (8 μg/
ml) found in strains containing the vGI-20 (IIUK2000 &
2eUK2000) deletion.
Assessment of virulence using a mouse model
The virulence of vaccine strains 316FUK2001, IIUK2001
and 2eUK2001 was compared with wild type strain
JD87/107 in a mouse model. Ten mice from each of five
groups (four inoculated with the different MAP strains
and a negative control group inoculated with PBS) were
killed at 4, 8 and 12 weeks post inoculation. Body, spleenand liver weights were recorded. Samples of the liver
were taken for bacteriological culture and histopath-
ology. Mean bodyweights increased with age, but no
statistically significant difference was observed in mean
body weight between any of the vaccine strains and the
control wild type strain at any of the time points
(p=0.11). There was strong evidence of a difference in
pattern over time between the mean rank spleen weight
expressed as a percentage of body weight of the mice
inoculated with the different MAP strains relative to
those receiving PBS, where those inoculated with MAP
had increasingly higher mean rank percentage weights
(P=0.006). Differences between the MAP strains were
not formally statistically significant (p=0.06) although
the control virulent strain JD87/107 showed an increase
in mean rank spleen weight percentage between weeks 4
and 8, and 316FUK2001 had an increase between
weeks 8 and 12. There was no statistical evidence for
differences in the mean levels of liver weight expressed
as a percentage of body weight either for different
strains or over time for any of the MAP strains (p = 0.2).
However, there was some evidence of a difference be-
tween the means for the MAP strains and the lower
mean weights associated with PBS (p = 0.018).
Table 2 Deleted region (vGI-20) in vaccine strains IIUK2000 and 2eUK2000
Gene Name Putative function Process
MAP1694 papA2 Polyketide synthase Cell Adhesion
MAP1695c Transcriptional regulator
MAP1696c hsp18_1 Heat Shock Protein Stress protein
MAP1697 Transcriptional regulator
MAP1698c hsp18_2 Heat Shock Protein Stress protein
MAP1699 thil Thiamine biosynthesis
MAP1700c β-lactamase
MAP1701c Biotin carboxylase subunit
MAP1702c Thioredoxin
MAP1703c Unknown
MAP1704c Glyoxalase Anti-host killing factor
MAP1705c Transcriptional regulator
MAP1706 Chitinase-like protein
MAP1707 3-ketoacyl-(acp) reductase Fatty Acid Metabolism
MAP1708 Phosphohydrolase-like protein
MAP1709 fadD11_2 LuxE like Acyl-protein synthetase Fatty Acid Metabolism
MAP1710 3-oxoadipate enol-lactonase Fatty Acid Metabolism
MAP1711c Transcriptional regulator
MAP1712 CoA-transferase family III
MAP1713 fadDE20_1 Acyl-CoA dehydrogenase Fatty Acid Metabolism
MAP1714 fadA_2 Acyl-CoA dehydrogenase Fatty Acid Metabolism
MAP1715 fadB_2 Acyl-CoA dehydrogenase Fatty Acid Metabolism
MAP1716 Short chain dehydrogenase Fatty Acid Metabolism
MAP1717 Unknown
*MAP1718c Low identity to MTB immunogen MPT63 Cell internalization factor
*MAP1719c Transcriptional regulator
*MAP1720 Nucleoside-diphosphate-sugar epimerases Cell envelope biosynthesis
*MAP1721c Transcriptional regulator
*MAP1722 IS900
*MAP1723 NADP oxidoreductase coenzyme F420-dependent
*MAP1724c Cytochrome b N
*MAP1725c Catalase Anti-host killing factor
*MAP1726c Transcriptional regulator
*MAP1727 Esterase_lipase Fatty Acid Metabolism
* = MAP specific genes.
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weeks post inoculation in all groups except the control
group inoculated with PBS. By 12 weeks post infection,
MAP was recovered from the tissues of only one mouse
inoculated with vaccine strain 2eUK2001 (mean count
46 cfu/g), from 6 mice inoculated with IIUK2001 (mean
counts between 46 and 315 cfu/g) and from all the mice
inoculated with the virulent JD87/107 strain (mean
counts 1.4-7 × 106 cfu/g) suggesting attenuation of each
of the vaccine strains (Figure 2a). Mean rank countsincrease over time for the JD87/107 strain, while drop-
ping for all the other MAP strains, this being most rapid
for the 2eUK2001 strain but ultimately most notable for
strain 316FUK2001. Statistical assessment of the effect
of the strain by time interaction on the mean rank count
indicate that differences exist in the abilities of the MAP
vaccine strains to survive or persist in mice (p=0.02).
Infections of the liver result in multifocal hepatitis
characterised by clusters of inflammatory cells. To meas-
ure the effect of the experimental infection with MAP,
Table 3 Tandem duplicated region (vGI-21) in vaccine strain IIUK2000
Gene Name Putative function Process
MAP2705c Ketosteroid isomerase
MAP2706c N-acylglucosamine 2-epimerase like
MAP2707c Signal protein
MAP2708c Glutamine amido transferase Amino acid-Lipid biosynthesis
MAP2709c tesB2 Acyl-CoA thioesterase II Amino acid-Lipid biosynthesis
MAP2710c pdxS Pyridoxal 5’-phosphate synthase Amino acid-Lipid biosynthesis
MAP2711c Nudix Hydrolase 26
MAP2712c Phosphatidylinositol alpha-mannosyltransferase
MAP2713c Lauroyl acyltransferase Lipid biosynthesis
MAP2714c pgsA CDP-alcohol phosphatidyltransferase Lipid biosynthesis
MAP2715c Diadenosine tetraphosphate
MAP2716c thrS threonyl-tRNA synthetase
MAP2717 Na+/H+ antiporter
MAP2718c N-alpha-acyl-glutamine aminoacylase Amino acid biosynthesis
MAP2719c Acyl-CoA thioesterase Amino acid biosynthesis
MAP2720c Aldo-keto reductase
MAP2721 Unknown
MAP2722c 2-Nitropropane dioxygenase
MAP2723c Unknown
MAP2724c Unknown
MAP2725c Transcriptional regulator
MAP2726c fdxA Ferredoxin Fe scavenging
MAP2727 S-adenosylmethionine-dependent methyltransferase
MAP2728 Transcriptional regulator
MAP2929c pcaB Lyase I like Benzoate metabolism
MAP2730c pcaG Protocatechuate 3,4-dioxygenase Benzoate metabolism
MAP2731c pcaH Protocatechuate 3,4-dioxygenase Benzoate metabolism
MAP2732c Hemerythrin oxygen binding like protein
MAP2733c Rieske (2Fe-2S) protein
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counted. Small numbers of leucocyte clusters (< 0.22
clusters per field) were observed in liver samples from
mice inoculated with PBS, though no acid fast bacilli
(AFB) were detected in any of these samples. Large
differences in the mean ranked density of leucocyte
clusters between strains were identified (p<0.001) with the
wild type strain JD87/107 having the highest mean ranked
densities of clusters (Figure 2b). Strain 2eUK2001 showed
evidence of higher mean rank densities than the
316FUK2001 and IIUK2001 strains (p = 0.03). The ranked
density of leucocyte clusters with AFB showed highly
statistically significant differences between the means of
MAP strains (p<0.001), with the JD87/107 strain consist-
ently showing higher mean densities, with this effect being
more pronounced from 8 weeks post infection (Figure 2c).
The vaccine strains all tended to exhibit increasingly lowermean ranked densities over the lifetime of the experiment
(p=0.002), with consistent patterns of differences between
strains (p=0.008): strain IIUK2001 showed the largest
mean rank densities, strain 316FUK2001 the lowest, with
2eUK2001 intermediate. The histopathology results show
that all strains elicited a similar inflammation at 4 weeks.
Only thereafter some differences between the inflamma-
tory responses to the strains became apparent. In addition,
the analysis of mean bacterial counts and AFB positive
clusters showed the reduced ability of the vaccine strains
to survive and persist within mice. Overall, these results
provide proof of attenuation of the vaccine strains with re-
spect to a wild type MAP strain.
Discussion
In this study, we examined genomic and phenotypic
characteristics of a panel of MAP vaccine strains obtained
Table 4 Tandem duplicated region (vGI-22) present in vaccine strain 316FNLD1978
Gene Name Putative function Process
MAP1750 Unknown
MAP1751 wcaG NAD-dependant epimerase/dehydratase Cell envelope biosynthesis
MAP1752c Aldo-keto reductase
MAP1753 Acyltransferase
MAP1754c uspA Adenine nucleotide alpha hydrolase Stress Protein
MAP1755c nirC Formate/nitrite transporter
MAP1756c rshA Anti-sigma factor
MAP1757c Sigma-70 factor
MAP1758c nrtC Acyl-CoA dehydrogenase
MAP1759c osmC Osmotic shock-like protein
MAP1760c tat translocated iron dependent peroxidise
MAP1761c Peptidase like lipoprotein
MAP1762c FTR1; high affinity iron transporter
MAP1763c Unknown
MAP1764 Unknown
MAP1765c rssA Patatin like esterase Fatty acid Metabolism
MAP1766c Cellobiose ABC transporter
MAP1767c ABC transporter
MAP1768c ABC transporter
MAP1769c Transcriptional regulator
MAP1770c Sigma-70 factor
MAP1771c IS900
MAP1772 Unknown
MAP1773c Nuclear transport factor 2 Steroid metabolism
MAP1774c pncA Isochorismatase Nicotinamide metabolism
MAP1775 doxX Unknown
MAP1776c Nucleotide phosphokinase-like
MAP1777c Unknown
MAP1778c aroK Shikimate kinase
MAP1779c Phosphotransferase
MAP1780c lipT Esterase_lipase Fatty acid Metabolism
MAP1781 lppI Lipoprotein
MAP1782c p450 cytochrome
MAP1783 Transcriptional regulator
MAP1784c Lipoprotein
MAP1785 IS900
MAP1786c Dihydropicolinate reductase-like
MAP1787c Short chain dehydrogenase
MAP1788 Transcriptional regulator
MAP1789 Unknown
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Table 5 Duplicated region (vGI-1b) in vaccine strain 316FUK2000
Gene Name Putative function Process
MAP0095c nuoI_1 NADH dehydrogenase subunit I
MAP0096c Membrane fatty acid desaturase Fatty acid metabolism
MAP0097c Membrane fatty acid desaturase Fatty acid metabolism
MAP0098c Transcription regulator expression regulator
MAP0099 csbD Stress protein stress response
MAP0100 gcs2 Glutamate-cysteine ligase glutathione biosynthesis
MAP0101 gcs2 Glutamate-cysteine ligase glutathione biosynthesis
MAP0102 Unknown
MAP0103c Unknown
MAP0104 IS1311 Transposase DNA mutator transposon
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low and high passage examples of the 316 F lineage. Using
a mouse model, we assessed the virulence ofrepresentative
clades of three vaccine strains (2e, II, 316 F) with respect
to a virulent MAP clinical isolate. The vaccine strains were
clearly attenuated with regard to their ability to survive
and persist in the mice as evidenced from the reduced
numbers of MAP recovered and reduced numbers of
leucocyte clusters containing AFB in the livers. This
supports previous studies showing decreased persistence
of the same 316 F and 2e strains in calves after 8 months
[29] and illustrates the utility of the C57BL/6 mouse
model for virulence studies.
Using a pan-genomic MAP/MAH microarray we
demonstrated that the genomes of all but one of the
316 F strains in the test panel contain the same full gen-
ome complement as the reference virulent bovine MAP
type II strain MAPK10. One 316 F strain obtained from
Norway (316FNOR1960) contained a single deleted re-
gion (vGI-19) spanning 21 ORF’s (including 10 MAP
specific genes). Two strains not of the 316 F lineage
(2eUK2000 and IIUK2000) contained a different deleted
region (vGI-20), identical in both strains, spanning 34
ORF’s (including 10 MAP specific genes). Specific PCR
for MAP1723 (Table 6), located within the vGI-20, on
2eUK2001 and IIUK2001 were negative confirming that
the vGI-20 region was not present in these strains
(Additional File 1). The inclusion of MAP-specific genes
in these deleted regions is an important observation as
these genes could provide the basis for differentiating
infected from vaccinated animals (DIVA). Indeed, the
deleted region vGI-19 contains part of the 38 kb patho-
genicity island described by Stratmann et al. (2004) [30]
which contains genes encoding a number of antigens
with diagnostic potential [31]. Both deleted regions
vGI-19 and vGI-20 contain genes potentially involved in
virulence and pathogenesis (Table 1) and their deletion
could therefore have a profound effect on the virulence
of these strains. In this study we demonstrated using amouse model that both vaccine strains 2eUK2001 and
IIUK2001 were attenuated with respect to a wild type
MAP strain. In addition, vaccine strain IIUK2000 and
IIUK2001 were found to contain a large 41 ORF tandem
duplication (vGI-21) which includes copies of benzoate
and lipid metabolic pathways. Vaccine strain 2eUK2000
comes from the same stock as 2eUK2001 and was
maintained at the VLA, UK for over 50 years on a min-
eral deficient medium (Watson Reid ‘A’ block) whilst
vaccine strain IIUK2000 was not. We suggest that the
vGI-21 duplication in vaccine strain IIUK2000 was
selected by these differences in media and fixed into the
genome to compensate in vitro for the deletion of lipid
biosynthesis and carbon usage repertoires, removed by
the vGI-20 deletion.
The large deletion vGI-19 present in vaccine strain
316FNOR1960 was not present in any of the other 316 -
F strains including an early low passage lineage
(316FCYP1966) and a more recent isolate (316 F2001)
shown to be significantly attenuated in our virulence
studies. Notably, part of vGI-19 is also present in the
same gene order within the related MAH104 genome
(GenBank reference CP000479). Together these suggest
that any ancestral precursor and therefore the original
316 F strain would be unlikely to be missing vGI-19. We
hypothesise that the vGI-19 deletion appeared in the
316FNOR1960 strain some point after its acquisition
and transfer to Norway in 1960 from the VLA, UK. This
strain is recorded as having been maintained, uniquely
on Dubos medium with added pyruvate [15] and we hy-
pothesise that this medium was at some point selective.
This is supported by the vGI-19 deletion in this strain
including gene homologues of glyoxylate enzymes
associated with pyruvate metabolism [32]. This strain
previously has been used successfully as a live vaccine
suggesting that it is attenuated. The knockout of the
glyoxylate shunt could significantly affect the strain’s abil-
ity to control anaerobic respiration [33] and intracellular
persistence [34], which may indicate that attenuation in
Table 6 PCR primer sets used in this study
Gene set Sequence
vGI-1b: (internal gene primer sets)
MAP0101.F GGTTACCGACTTGGTCCAGA
MAP0101.R CCCGTCAGATCCATTACGAC
MAP0103.F2 GAGCGCCAACCTATCTCAAC
MAP0103.R TGGTTTGGAGATCCCTGAAG
vGI-19 (internal gene primer set)
MAP3733c.F TTCATGTTGTTCCTCACCCG
MAP3733c.R CATCGCGAGCGTAGCCGCTG
vGI-20 (internal gene primer set)
MAP1723.F GGAGTATGGAACCATCGCTG
MAP1723.R TGATGTAACGGGCGTGCAAG
vGI-21 (specific for tandem duplicated region in IIUK2000/1)
MAP2705.SEQ2 CGATGAAGGCCTACTGGTC
MAP2733.R TCAACTGGCTCCTCCTTTTG
vGI-22 (specific for tandem duplicated region in 316FNLD1978)
MAP1789.F TTTGGCACTACAACGAGCTG
MAP1750.R GATCGAGAAGAGGGGAGTCA
MAP2114c (single copy gene for control PCR)
MAP2114c.F TGGAAGCTACCCAAATCACC
MAP2114c.R GAGAAGTAGGCCGCGTAGTC
IS900
AV-1 ATGTGGTTGCTGTGTTGGATGG
AV-2 CCGCCGCAATCAACTCCAG
pre16SrRNA
pre16SrRNA.R GCGCAGCGAGGTGAATTT
pre16SrRNA.F TTTGGCCATACCTAGCACTCC
Tellurite (tehB)
MAP3730.F GGTTTGACGACAGAGATGCG
MAP3730.R GGCATGGTGTACGACAAGGA
MIRU3 (MAP3981-2)
MIRU3.F ACATTCACCCTGTCCATTCC
MIRU3.R CCTCCTTACGGAGCAGGAA
IS900(MAP0034)
MAP0033c.F AGCTGCCGGGAGTTGATCT
MAP0035.R TCACGGCTCACCGCACGCT
IS900(MAP0159c)
MAP0158.F CCCGTGACAAGGCCGAAGA
MAP0160.R CGTTTTGCACCTCGATGGCC
IS900(MAP0967)
MAP0966c-MAP0967.F CGTGACGAACGACATGTGTT
MAP0967-MAP0968.R GCTCGAGACATTTAGCCCAC
IS900(MAP1033)
MAP1032c.F GTAGAACCCGACCAGCAGC
MAP1034c.R GACCTGGCACCTGTATCCC
Table 6 PCR primer sets used in this study (Continued)
IS900(MAP1722)
MAP1720-MAP1721c.F CTAAGGTGGCCAGCGTTTCT
MAP1723.R GGTTGGAGACAACCTCGTTC
IS900(MAP1771c)
MAP1770c.F ACAATTCGGCGATCGTCTCG
MAP1772.R CGCGGACAGACACAGGTAGG
IS900(MAP1785)
MAP1784c.F GTCGACCATCGCTCTTCCCT
MAP1786c.R ATCGGTGTCGAGGACATTCC
IS900(MAP1793c)
MAP1792.F CAATGGATGGTCGTCACCTG
MAP1794.R CGGCCCGCTTGATCCATTTG
IS900(MAP2034c)
MAP2033-MAP2034c.F CCGCAAGTAGTGCACTATGG
MAP2035.R TATTCGGGGTTGTTCAGGGA
IS900(MAP2108)
MAP2105.F CAGGCACGGAACACAGTTCG
MAP2109c.R TGTTCGGCTACGGCATACTG
IS900(MAP2157)
MAP2156.F CTGCAAACACAGCCCAATC
MAP2158.R CAACTTCGGCAAGTTCACC
IS900(MAP2203c)
MAP2202c.F TCCCGGTAGAAGATCATGTG
MAP2204c.R GACAATCTGCCGTCGTATCA
IS900(MAP2444c)
MAP2443.F AACCTTGACCCACACCTTCC
MAP2445.R TGAGCTCGCCGGCGAAATA
IS900(MAP2577)
MAP2567c.F CGTTCTGGGCATCCATCGACG
MAP2578.R TCACGGCGGTCAGGTTACTTC
IS900(MAP3480)
MAP3479c.F GTTGAACTTTCCGACCAACC
MAP3480-3481.R GGTTAGCGGGAGAAAAGCTC
IS900(MAP4066)
MAP4065.F TGGGCCTGAGGTCAGAACCA
MAP4067c.R GAAGACCACCTCTACCTCAC
IS900(MAP4281)
MAP4280.F GCTGACCGAGAAGGGCTAC
MAP4282.R CGTAAGTGACTGGCTCATGG
MAP gene annotation corresponds to GenBank AE016958.
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strain was shown to be highly immunogenic in goats [35]
and forms part of a 316 F/2e live commercial vaccine
product (Paratuberkulose-vaksine, National Veterinaria
Institute, Oslo, Norway) however there is no evidence that
Table 7 MIRU, vGI, Tellurite MIC and IS900 / MAP0101 / MAP0103 genome copy numbers
Strain MIRU3 vGIs* Tellurite MIC Copy number relative to MAP2114c
bp (copy no) μg/ml IS900 MAP0101/ MAP0103
316FNLD2008 244 (1) 128 17 1
316FUK2001 244 (1) nd nd nd
316FNLD1978 244 (1) 22dp 128 19 1
316FUK2000 297 (3) 1bdp 128 16 2
316FNEO4/81 297 (3) nd 17 1
316FNEO8/81 297 (3) nd 17 1
316FNEO68451-2 297 (3) nd 17 1
316FNEO69341 297 (3) nd 17 1
316v 297 (3) nd 16 1
316FCYP1966 297 (3) > 512 16 1
316FNOR1960 297 (3) 19dl 64 16 1
IIUK2000 297 (3) 20dl & 21dp 8 13 1
2eUK2000 297 (3) 20dl 8 13 1
MAPK10 297 (3) 128 17 1
CAM87 297 (3) 256 17 1
nd = not done.
* vGI status for vGI-1b, vGI-19 - vGI-22 either duplicated (dp) or deleted (dl), else no entry designates present as a single copy region.
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effectively, on goats in the 1960-70’s [15].
We tested the potential impact provided by deletion of
the putative tellurite resistance gene (tehB) included in
vGI-19 on 316FNOR1960 phenotype. Tellurite is highly
toxic to bacteria due to its action on DNA synthesis. It
is an important mechanism by which animals combat
intracellular microorganisms [27] and was used in early
studies as a tuberculosis/leprosy therapeutic [36]. Bacter-
ial resistance to tellurite is inducible, is associated with
virulence [28] and is linked to catalases which are
required to process the superoxide anions generated as a
result of bacterial metabolic mechanisms used to inacti-
vate tellurite. We show a significantly increased sensitiv-
ity to tellurite in 316FNOR1960 whilst other 316 F
strains either matched or exceeded the resistance of the
two wildtype strains tested (K10:bovine, CAM87:cap-
rine). Interestingly the strains most sensitive to tellurite
were IIUK2000 and 2eUK2000 which lack the tehB gene.
The metabolism of tellurite generates high reactive oxy-
gen species which subsequently need to be de-toxified
by catalase [37]. Significantly the vGI-20 deletion
in these strains includes loss of the catalase gene
homologue MAP1725c. Both vaccine deletion regions
thus involve alterations in metabolic pathways associated
with deactivation of high reactive oxygen species tox-
icity, which suggests this may be an important mechan-
ism underlying attenuation in these strains.
Several of the other vaccine strains tested are also
reported to have been maintained on markedly different
media which may have similarly promoted or selectedfor genomic and phenotypic diversities. 316FNLD1978,
available as a heat killed vaccination for dairy cattle since
1985 [38], was found to contain a large tandem duplica-
tion (vGI-22) unique to this strain. It is notable that this
isolate was selectively subcultured on potato starch
medium to enhance its growth (P. Willemsen personal
communication) and now grows with difficulty on other
media. It is tempting to speculate that the acquisition of
extra copies of 14 ORFs including cell wall, fatty acid bio-
synthesis genes and two extra copies of IS900 are a direct
result of the selective process performed on this strain.
We demonstrated in this study that vaccine strain
316FUK2001 was clearly attenuated with respect to wild
type MAP strain JD87/107. The vGI-19 deletion found
in 316FNOR1960 and the vGI-20 deletion found in
2eUK2000 and IIUK2000 were not detected by PCR in this
strain suggesting that attenuation in this strain is due to dif-
ferent genetic polymorphisms. A duplicated region (vGI-
1b) was detected in vaccine strain 316FUK2000, which may
possibly have arisen as an adaptation to growth on liquid
Watson Reid media.
Insertion sequences bordering specific genomic regions
have previously been associated with variably tandem
duplicated [39] and possibly large genomic inversions [40]
and contribute highly to the degree of plasticity in the
MAP genome. Variations in copy number of insertion
elements including IS900, IS1311, IS256 and IS1652-like
elements were seen between vaccine strains and virulent
isolates. An IS1311 was found immediately bordering the
vGI-1b region duplicated in 316 F-UK2000 but not other
316 F strains. Similar genomic variations including vGI-1b
Figure 2 (See legend on next page.)
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Figure 2 Virulence assessment of vaccine (2eUK2001, 316FUK2001, IIUK2001) and wild type (JD87/107) MAP strains in a mouse model.
A. Quartile-Based Box and Whisker plots of bacterial load (CFU/g) in the liver at 4, 8 and 12 weeks post-infection. B. Quartile-Based Box and
Whisker plots of mean ranked density of leucocyte clusters in the liver at 4, 8 and 12 weeks post-infection. C. Quartile-Based Box and Whisker
plots of mean ranked density of leucocyte clusters with AFB in the liver at 4, 8 and 12 weeks post-infection. * indicates an unusually large or
small observation (outlier). Values beyond the whiskers are outliers. The top of the box is the third quartile −75% of the data values are less than
or equal to this value. The bottom of the box is the first quartile −25% of the data values are less than or equal to this value. The median is
shown within the box. The whiskers extend to the highest and lowest data values which have not been identified as outliers.
BMC1010
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definitive element of MAP found in all clinical and vaccine
strains, was also shown to be present in a variety of copy
numbers. This work used comparative ratios of qPCR
signals to estimate the average number of IS900 copies per
cell per culture relative to two single copy MAP genes
using an assumption determined from a MAP assembled
genome sequence that MAPK10 would contain 17 copies.
Our results confirm previous studies showing the vaccine
strain 316v used in Australia for ELISA testing [41]
contains one less genomic copy of IS900 [42] than most
other 316 F strains [25]. Vaccine strain 316FNLD1978
exhibited higher gene signal ratios consistent with the two
extra copies of IS900 copies inside the duplication of vGI-
22. Vaccine strains IIUK2000 and 2eUK2000 contained
lower signal ratios consistent with loss of an IS900 copy
inside the deletion region vGI-20. Consistently however
the calculated IS900 copy number in these strains was
much lower than expected using the ratio method. Using
site specific PCR we confirmed 16 IS900 filled insertion
sites in the genomes of these strains whereas the ratio
method, using MAPK10 as a standard, predicted only 13
copies. The reason could be technical, perhaps involving
incomplete bacterial lysis of these unusual strains, how-
ever IS900 is known to replicate in episomal minicircles
[43] and when all consensus insertion sites are filled they
may exist as extra genomic components awaiting trans-
position. If this is indeed the case, virulent MAP strains
would have the capacity to contain more than the
predicted 17 IS900 copies per cell. This could be an im-
portant factor in studies relying on qPCR to determine ac-
curate estimates of MAP load [44].
MIRU3 is a short tandem repeat sequence located within
the sensX3-regX3 two component signalling system that
controls carbon source usage and mechanisms reducing
damaging reactive oxygen species generated by aerobic me-
tabolism [45]. The attenuated BCG vaccine characteristic-
ally contains a low MIRU3 tandem repeat copy number
which has been suggested to be involved in the control of
sensX3-regX3 expression [46]. In this study 316 F strains
(316FNLD1978, 316FUK2001, 316FNLD2008) had low
MIRU3 copy numbers whilst others, mostly originating
from older culture stocks, were larger. This may represent
a potential for genomic drift within recent 316 F lineages
and could be used as a marker for the most current 316 FVLA, UK strain but may also be suggestive that loss of
intracellular persistence in full genome complement 316 F
strains may be associated with reduced transcriptomic sig-
nalling capacity. It will be of interest therefore in future
total genome sequencing studies to compare dysfunctional
SNP variations within signalling features of 316 F strain
genomes.
Conclusions
This study has shown that significant genomic diversity
exists between MAP vaccine strains and within the
316 F lineage. These include large deletions, duplications
and changes in insertion sequence copies. These
mutations were probably derived in a classical manner
by selective subculture on laboratory media and in some
cases have led to significant alterations of phenotype and
attenuation. There were 25 MAP specific gene deletions
identified of which at least one could be linked to
phenotypic change that would disadvantage its persist-
ence in the host and thus associates it with virulence.
Furthermore, these MAP-specific gene deletions could
provide the basis for a DIVA diagnostic for use with
these vaccines. Overall, this work illustrates that MAP
genome plasticity can be influenced by in vitro culture
over long periods and a robust definition of vaccine
strain genome lineage will be necessary in the future to
guarantee consistency between studies.
Methods
Strains and culture media
MAP strains used in this work, their origins, sources
and media used for propagation are described in
Table 8.
DNA extraction
DNA was extracted for typing and arrays using a previ-
ously described protocol [26]. Briefly, 1x109 cells of
cultures grown on liquid Middlebrook 7H9 medium for
up to 12 weeks were pelleted, washed once in 1x PBS,
then resuspended in 650 μl mycobacterial lysis buffer
(0.5 M EDTA –pH 8.0-, 5 M NaCl, 1 M TrisHCl, 10%
SDS and 8.6 ml H2O). Colonies were emulsified by passing
10 times through a 25 G needle, and treated overnight at
37°C with 5 μl lysozyme (Stock 100 mg/ml: Sigma), 10 μl
proteinase K (Stock 10 mg/ml: Sigma) and 4 μl lipase
Table 8 Details of MAP strains used in this study
Name Origin and source Medium used for maintenance and
propagation
316FNOR 1960
(Vaccine strain)
Obtained from the VLA in 1960 and used in a vaccine trial in goats in Norway
during the 1960s [15]. Maintained at the Norwegian Veterinary Institute, Oslo.
Selective Dubos medium [47] supplemented
with mycobactin (2 μg/ml) and pyruvate
(4 mg/ml)
316FCYP1966
(Vaccine strain)
Obtained from the VLA in 1966 as lyophilised aliquots and used to vaccinate
goats in Cyprus during the 1960s [18]. Strain used in this study was recovered
from an aliquot lyophilised on 04 January 1966 and resuscitated in 2009 with limited
passage since.
7H9*
316FNLD1978
(Vaccine strain)
Obtained from the VLA in 1978 and used as a killed vaccine [38].
Maintained at the Central Veterinary Institute, Lelystad, Netherlands.
Potato starch medium (P.Willemsen
personal communication)
316FNEO4/81
(Vaccine strain)
Neoparasec vaccine (Merial, France) subcultures from a stock [25] assumed to be
derived from a 316 F Weybridge UK strain purchased in the 1980s.
7H9* or 7H11**
316FNEO8/81
(Vaccine strain)
316FNEO68451-2
(Vaccine strain)
316FNEO69341
(Vaccine strain)
316v Australian strain derived from a variant labelled 316f around 1986 [48] which itself
was obtained from a New Zealand source who obtained the strain in the early 1980s.
Maintained at the University of Sydney, Sydney, Australia.
Mycobactin free medium but grew poorly
(R Whittington, personal communication)
316FUK2000
(Vaccine strain)
Obtained from the VLA in 2000 and maintained at St George’s Hospital Medical
School, London, UK, with limited passage.
Liquid Watson Reid†
316FUK2001
(Vaccine strain)
Obtained as a lyophilised stock from the VLA in 2001 and maintained at the
Moredun Research Institute, Scotland, UK.
7H11**
316FNLD2008
(Vaccine strain)
Obtained from VLA in 2008 and maintained at the Central Veterinary Institute,
Lelystad, Netherlands
HEYM
IIUK2000
(Vaccine strain)
Obtained from the VLA in 2000 and maintained at St George’s Hospital Medical
School, London, UK.
Liquid Watson Reid† [14]
IIUK2001
(Vaccine strain)
Obtained as a lyophilised stock from the VLA in 2001 and maintained at the
Moredun Research Institute, Scotland, UK.
7H11**
2eUK2000
(Vaccine strain)
Obtained from the VLA in 2000 and maintained at St George’s Hospital Medical
School, London, UK.
Liquid Watson Reid ‘A’ Block†† medium
2eUK2001
(Vaccine strain)
Obtained as a lyophilised stock from the VLA in 2001 and maintained at the
Moredun Research Institute, Scotland, UK.
7H11**
MAPK10 (Wild
type strain)
Purchased from ATCC: BAA-968. Sequenced reference strain isolated from a
cow in 1990.
7H9* or 7H11**
CAM87 (Wild
type strain)
MAP Type III strain isolated from a goat in 2005 [26] and maintained at
the Universidad Complutense de Madrid, Madrid, Spain.
7H9*
JD87/107 (Wild
type strain)
Isolated from a deer in 1987 and maintained at the Moredun Research Institute,
Scotland, UK.
7H11**
*7H9: Middlebrooks 7H9 (Becton Dickinson, UK) supplemented with 2 mg/L Mycobactin J (Allied Monitor, USA), 0.5% glycerol, 10% oleic acid-albumin-dextrose-
catalase (OADC) enrichment medium (Difco, UK), 25 mg/L amphotericin B, 35 mg/L naladixic acid and 35 mg/L vancomycin.
**7H11: Middlebrooks 7H11 (Becton Dickinson, UK) agar supplemented with 2 mg/L Mycobactin J (Allied Monitor, USA), 2.5% glycerol (v/v), 10% OADC (v/v)
enrichment medium (Difco, UK), 20% (v/v) new born calf serum, 0.3 g/L asparagine, Mycobacteria Selectatabs (10 mg/L amphotericin B, 200,000 units/L polymixin
B, 100 mg/L ticarcillin and 10 mg/L trimethoprim [MAST Laboratories Ltd, UK]).
†Liquid Watson Reid: Asparagine 5 g/l, Potassium dihydrogen phosphate 2 g/l, Magnesium suphate 1 g/l, Tri-ammonium citrate 2 g/l, Sodium chloride 2 g/l, D(+)
Glucose 10 g/l, Glycerol 48 ml/l, Ammonium iron (III) citrate brown 0.075 g/l, 1.33mls of Supplement A: 2 g/l Zinc sulphate, 2 g/l Copper sulphate, 1 g/l Cobalt
nitrate, 1.33mls of Supplement B; 50 g/l Calcium chloride.
††Liquid Watson Reid ‘A’ Block: as Watson Reid medium but without supplements A and B.
Bull et al. BMC Microbiology 2013, 13:11 Page 13 of 17
http://www.biomedcentral.com/1471-2180/13/11(Stock 121 mg/ml Sigma). Samples were ribolysed (Lysing
Matrix B; Qbiogene) at 6,500 rpm for 50 sec, iced for
10 min then 400 μl of lysate added to 400 μl of Qiagen
DNAeasy AL lysis buffer, mixed and applied to a DNAeasy
column. 200 μl of 100% ethanol was added and columns
centrifuged at 8,000 rpm for 1 min, washed in 500 μlQiagen Lysis buffer 1 and 2, then eluted in 90 μl DNA/
RNAse free H2O overnight on the column at 4°C.
MIRU3 typing and IS900 locus PCR
Five microlitres of MAP DNA extracted from test strains
was amplified for MIRU [49] or IS900 [40] as previously
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spanning the MAP3982-MAP3983 locus or with IS900
locus specific primers designed to amplify across the
complete IS900 insertion from immediately adjacent loci
(Table 6). All PCR reactions used 1x Expand reaction buf-
fer containing 1.5 mMMgCl2, 10% DMSO, 100 μM dNTP
and 1 unit Expand High Fidelity Taq polymerase (Roche).
Cycling conditions were: 95°C: 3 min: 1 cycle; 94°C: 30 sec :
60°C: 30 sec : 72°C : 1 min : 35 cycles; 72°C : 5 min : 1 cycle.
Confirmation of amplicon product size in bp was made on
1.8% agarose gels.MAPAC microarray hybridisation and analysis
DNA from the test strain and reference MAP K-10 strain
were fluorescently labelled and hybridised to the micro-
array using protocols described previously [50]. Briefly,
1 μg of DNA was labelled by random priming with
Klenow polymerase to incorporate either Cy3 or Cy5
dCTP (GE Healthcare) for the test strain and reference
strain respectively. Equal amounts of the Cy3 and Cy5 la-
belled samples were co-purified through a Qiagen
MinElute column (Qiagen), mixed with a formamide-
based hybridisation solution (1×MES, 1 M NaCl, 20%
formamide, 0.02 M EDTA, 1% Triton) and denatured at
95°C for 2 min. The labelled sample was loaded on to a
prehybridised (3.5×SSC, 0.1% SDS, 10 mg/ml BSA) micro-
array under two 22×22 mm LifterSlips (Erie Scientific),
sealed in a humidified hybridisation cassette (Corning)
and hybridised overnight by immersion in a waterbath at
55°C for 16–20 h. Slides were washed once in 400 ml
1×SSC 0.06% SDS at 55°C for 2 min and twice in 400 ml
0.06×SSC for 2 min. Microarrays were scanned using
an Affymetrix 428 scanner, and signal intensity data
were extracted using BlueFuse for Microarrays v3.5
(BlueGnome). The intensity data was further post-
processed using BlueFuse to exclude both controls and
low confidence data (p<0.1) prior to normalisation by 2D
Lowess (window size=20) and median centring. Further
analysis of the normalised data was undertaken using
BlueFuse, GeneSpring 7.3.1 (Agilent Technologies) and
Eisen Cluster [51]. Fully annotated microarray data
has been deposited in BμG@Sbase (accession number: E-
BUGS-264; http://bugs.sgul.ac.uk/E-BUGS-264) and also
ArrayExpress (accession number: E-BUGS-264).qPCR
Relative copy number of amplicons were generated
from IS900, MAP0101 and MAP0103 primer sets and
compared against absolute amplicon numbers obtained
from a MAP2114c primer set (Table 6). Reactions
comprised 2 μl genomic DNA sample, 12.5 μl Power SYBR
green mastermix (Applied Biosystems, Cat 4368706), 2pMoles appropriate primer pairs, made to 25 μl with
RNAse free H2O. PCR cycling used 95°C:15mins (1 cycle);
at 95°C:30secs, 58°C :1 min, 72°C:1 min (40 cycles) with
data collection at 76°C (10secs) using a CFX96 qPCR cycler
(BioRad, UK). Sample copy numbers were estimated from
an averaged value of three qPCR’s on each sample using a
dilution curve of a control stock total genomic DNA MAP
K-10 preparation serially diluted 10 fold to contain between
1 × 102-106 genome copies.Tellurite MIC
Cultures of MAP strains were grown in conventional li-
quid media to exponential phase for 6 weeks then adjusted
to 104 cfu/ml using OD550. Aliquots (10 μl) were
inoculated onto solid RAF medium in petri dishes
containing serial dilution of potassium tellurite to final
concentrations of 512, 256, 128, 64, 32, 16, 8, 4 or 0 μg/ml
and incubated at 37°C. MIC’s were taken as the least tel-
lurite concentration able to inhibit >90% growth, seen as
black colonies, after 6 weeks of growth and 12 weeks
growth for strain IIUK2000 which was slower to grow
in vitro.Assessment of virulence using a mouse model
The virulence of vaccine strains 316FUK2001, IIUK2001
and 2eUK2001 was compared with wild type strain JD87/
107 in a mouse model. 316FUK2001, IIUK2001 and
2eUK2001 were selected to represent the three different
vaccine strains that have been used for control of JD over
the years. JD87/107 was selected as the control strain as
this was the virulent wild type strain that was used previ-
ously in our laboratory to optimise the mouse model and
PBS was used as a negative control. C57BL/6 mice of ap-
proximately five weeks old and between 20 and 25 g in
weight were purchased from Harlan UK, Shaws Farm,
Blackthorn, Bicester, Oxon OX25 1TP. The mice were indi-
vidually weighed and randomly assigned to five groups of
30. One negative control group was inoculated with 0.1 ml
of sterile PBS. The remaining groups were inoculated
intraperitoneally with 1.1 to 1.4 × 108 organisms in 0.1 ml
PBS of one of the MAP strains 2eUK2001, IIUK2001,
316FUK2001 and JD87/107. The inocula were prepared as
previously described [52] and enumerated by performing a
microscopic count. Ten mice from each group were killed
at 4, 8 and 12 weeks post inoculation by exposure to a mix-
ture of carbon dioxide and halothane gas followed by cer-
vical dislocation. Each mouse was weighed and the body
weight recorded. The spleens and livers were removed
aseptically and weighed. The respective weights were
expressed as a percentage of body weight for each
mouse. Approximately 0.1 g of liver was removed for
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10% formal saline for histopathological examination.
Hepatic bacterial load was assessed by using serial
dilutions of a 10% (wt/wt) liver homogenate in PBS. 0.1 ml
of each dilution was inoculated onto 7H11 agar with
supplements as detailed in Table 8 and incubated at 37°C
for up to 16 weeks. Colony counts for each animal repli-
cate were estimated by fitting a generalised linear model
to the dilution assay counts assuming an overdispersed
Poisson response and a logarithmic link function while fit-
ting the logarithm of the dilution as an offset variable to
the fixed mean. It was assumed that observations greater
than 200 CFU per field could not be quantified accurately,
and such observations were included in the likelihood as
taking unknown values greater than this threshold.
The fixed liver samples were given a random code to
assure that the samples were assessed blind by the path-
ologist. The samples were processed to paraffin wax and
5 μm sections prepared. The sections were stained with
haematoxylin and eosin (H&E) and Ziehl-Neelsen (ZN)
method . Using an Olympus BX50 microscope, the num-
ber of leucocyte clusters was counted in approximately
100 fields at ×200 magnification from each individual
animal using an eyepiece graticule (Pyser-SGI Ltd,
NE35-24 mm) and the counts normalised to 1 field. A
leucocyte cluster was defined as an accumulation of
more than 10 mononuclear leucocytes. The infectious
load of each animal was assessed by counting leucocyte
clusters containing AFB. Because the detection of AFB
requires higher magnification (x400-600), the number of
leucocyte clusters with AFB was assessed separately. De-
pending on the original leucocyte cluster density, up to
sixty leucocyte clusters were assessed in detail and the
proportion of leucocyte clusters containing AFB
determined. Based on the leucocyte cluster counts and
the proportion of leucocyte clusters containing AFB, the
infectious load was expressed as the mean number of
AFB positive leucocyte clusters per field.
All data were analysed by fitting a linear mixed model to
either the data as specified above or to the ranks of these
data, with this choice being made on the basis of the nor-
mality of residuals in the model fitted to the original data.
The mixed model approach was preferred to traditional
ANOVA to better allow for replicates missing at random
from the sample. Strain and Week and interactions were
fitted as fixed effects, animal replicate as a random re-
sidual effect. Statistical analysis was carried out using
Genstat version 14 and using user-defined macros in Excel
2007. All statistical analysis and derivations of P values are
provided in Additional File 2).
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